Invest in the
Future of Pharma
Groff North America presents a strategic investment opportunity at the intersection of botanical biotechnology, federal compliance, and global pharmaceutical supply chain infrastructure.
Investment Highlights
Why Groff North America is positioned for exponential growth.
Regulatory Moat
Operating under 6 specific DEA Schedule I registrations, we possess rare federal authorization for bulk manufacturing, import/export, and research. This compliance infrastructure establishes a formidable barrier to entry and positions us as a critical partner for multinational pharmaceutical companies.
Capital Efficiency
We have developed a robust clinical pipeline and extensive intellectual property portfolio with high capital efficiency. Our disciplined allocation strategy ensures funding is directed exclusively toward value-creating clinical and regulatory milestones.
Defensible IP
Our proprietary library of over 300 sequenced and genotyped cultivars, combined with our advanced molecular breeding technology, establishes a deep, defensible moat of patentable traits and novel botanical APIs.
Billion-Dollar Markets
We are advancing therapeutics for high-unmet-need indications in neurology, oncology, and inflammation. Our platform approach allows us to systematically address multiple billion-dollar-plus market opportunities.
Join Our Mission
We are currently inviting accredited investors to participate in our Series B round. Contact our Investor Relations team to request access to our data room.